Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 8;13(5):775.
doi: 10.3390/brainsci13050775.

L-DOPA Improves Ventilation but Not the Ventilatory Response to Hypercapnia in a Reserpine Model of Parkinson's Disease

Affiliations

L-DOPA Improves Ventilation but Not the Ventilatory Response to Hypercapnia in a Reserpine Model of Parkinson's Disease

Monika Jampolska et al. Brain Sci. .

Abstract

Parkinson's disease (PD) is a neurological disorder characterized by progressive degeneration of the substantia nigra that affects mainly movement control. However, pathological changes associated with the development of PD may also alter respiration and can lead to chronic episodes of hypoxia and hypercapnia. The mechanism behind impaired ventilation in PD is unclear. Therefore, in this study, we explore the hypercapnic ventilatory response in a reproducible reserpine-induced (RES) model of PD and parkinsonism. We also investigated how dopamine supplementation with L-DOPA, a classic drug used to treat PD, would affect the breathing and respiratory response to hypercapnia. Reserpine treatment resulted in decreased normocapnic ventilation and behavioral changes manifested as low physical activity and exploratory behavior. The respiratory rate and the minute ventilation response to hypercapnia were significantly higher in sham rats compared to the RES group, while the tidal volume response was lower. All of this appears to be due to reduced baseline ventilation values produced by reserpine. L-DOPA reversed reduced ventilation, indicating a stimulatory effect of DA on breathing, and showed the potency of DA supplementation in restoring normal respiratory activity.

Keywords: L-DOPA; Parkinson’s disease; breathing; hypercapnia; rat model; reserpine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Tidal volume (A), frequency of breathing (B), and minute ventilation (C) during air breathing (normocapnia) and ventilatory response to hypercapnia in sham (blue line) and reserpine-treated rats (red line). Tidal volume (D), frequency of breathing (E), and minute ventilation (F) reactivity to hypercapnia expressed as a percentage of baseline (normocapnia). The data are presented as mean ± SEM; * p < 0.05 vs. normocapnia value, × p < 0.05 vs. 4% CO2 response, # p < 0.05, vs. sham or reserpine group.
Figure 2
Figure 2
Tidal volume (A), frequency of breathing (B), and minute ventilation (C) during air breathing (normocapnia) and ventilatory response to hypercapnia in sham rats (blue line) treated with L-DOPA (red line). Tidal volume (D), frequency of breathing (E), and minute ventilation (F) during air breathing (normocapnia) and ventilatory response to hypercapnia in reserpine rats (blue dashed line) treated with L-DOPA (red dashed line). The data are presented as mean ± SEM; * p < 0.05 vs. normocapnia value, × p < 0.05 vs. 4% CO2 response, # p < 0.05, vs. reserpine group.
Figure 3
Figure 3
Tidal volume (A,D), frequency of breathing (B,E), and minute ventilation (C,F) during air breathing (normocapnia) and ventilatory response to hypercapnia in reserpine rats (blue dashed line) treated with L-DOPA; 25 mg/kg (red dashed line) and 100 mg/kg (green dashed line). The data are presented as mean ± SEM; * p < 0.05 vs. normocapnia value, × p < 0.05 vs. 4% CO2 response within the same group, # p < 0.05, vs. reserpine groups.
Figure 4
Figure 4
Tidal volume (A,D), frequency of breathing (B,E), and minute ventilation (C,F) reactivity to hypercapnia expressed as a percentage of baseline (normocapnia) in reserpine rats (blue dashed line) treated with L-DOPA; 25 mg/kg (red dashed line) and 100 mg/kg (green dashed line). The data are presented as mean ± SEM; * p < 0.05 vs. normocapnia value, × p < 0.05 vs. 4% CO2 response within the same group, # p < 0.05, vs. response without L-DOPA treatment.

Similar articles

References

    1. Triarhou L.C. Introduction. Dopamine and Parkinson’s disease. Adv. Exp. Med. Biol. 2002;517:1–14. - PubMed
    1. Dragicevic E., Schiemann J., Liss B. Dopamine midbrain neurons in health and Parkinson’s disease: Emerging roles of voltage-gated calcium channels and ATP-sensitive potassium channels. Neuroscience. 2015;284:798–814. doi: 10.1016/j.neuroscience.2014.10.037. - DOI - PubMed
    1. Aquino Y.C., Cabral L.M., Miranda N.C., Naccarato M.C., Falquetto B., Moreira T.S., Takakura A.C. Respiratory disorders of Parkinson’s disease. J. Neurophysiol. 2022;127:1–15. doi: 10.1152/jn.00363.2021. - DOI - PubMed
    1. Kaczyńska K., Orłowska M.E., Andrzejewski K. Respiratory Abnormalities in Parkinson’s Disease: What Do We Know from Studies in Humans and Animal Models? Int. J. Mol. Sci. 2022;23:3499. doi: 10.3390/ijms23073499. - DOI - PMC - PubMed
    1. Seccombe L.M., Giddings H.L., Rogers P.G., Corbett A.J., Hayes M.W., Peters M.J., Veitch E.M. Abnormal ventilatory control in Parkinson’s disease—Further evidence for non-motor dysfunction. Respir. Physiol. Neurobiol. 2011;179:300–304. doi: 10.1016/j.resp.2011.09.012. - DOI - PubMed

LinkOut - more resources